RxDoctor Payments Data

Bryan Cooper, NP

Family · Camano Island, WANPI 1689900466

Payments from drug & device makers

$1,050in general payments, 2019–2025

Across 51 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$430
  • Collegium Pharmaceutical, Inc.$257
  • Novo Nordisk$95
  • AbbVie$77
  • Exact Sciences$52
  • Biohaven Pharmaceutical Holding Company Ltd.$28
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,050 in reported general payments places this provider in the 80th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$39,652
Medicare patients
94
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$16,066
JardianceEmpagliflozin12$11,573
DilantinPhenytoin Sodium Extended26$2,467
Atorvastatin Calcium137$2,170
Lisinopril159$1,070
Tamsulosin Hcl45$962
Duloxetine Hcl25$940
Losartan Potassium76$916
Fluticasone Propionate24$645
Amlodipine Besylate87$634
Levothyroxine Sodium62$540
Simvastatin41$455
Albuterol Sulfate HfaAlbuterol Sulfate25$453
Gabapentin27$393
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide49$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$18$18,53341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,706 family providers in Washington.

Other family in Camano Island

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →